Abstract
We assessed virological outcomes of darunavir use in France from 2012 to 2016, in three groups of people living with HIV (PLHIV): (i) antiretroviral (ARV)-naive PLHIV; (ii) ARV-experienced PLHIV switching to darunavir while failing therapy; and (iii) ARV-experienced PLHIV switching to darunavir while virologically controlled. Virological success (VS) was defined as a plasma HIV-1 viral load (VL) <50 copies/mL and virological failure (VF) as two consecutive VL >50 copies/mL or one VL >50 copies/mL followed by a treatment switch prior to the next VL measurement. The cumulative incidence of VS was assessed considering darunavir discontinuation, loss to follow-up and death as competing risks, while estimates of cumulative incidence of VF accounted for loss to follow-up and death. Among the 3235 ARV-naive PLHIV initiating darunavir, the 4 year cumulative incidence of VS was 80.9% and was associated with lower VL and higher CD4 cell counts. Among the 3485 ARV-experienced PLHIV switching to darunavir while failing therapy, the 4 year cumulative incidence of VS was 82.2% and was associated with lower VL. Among the 3005 ARV-experienced PLHIV switching to darunavir while virologically controlled, the 4 year cumulative incidence of VF was...Continue Reading
References
Apr 10, 2007·Lancet·Bonaventura ClotetUNKNOWN POWER 1 and 2 study groups
Jul 10, 2007·Lancet·José Valdez MadrugaUNKNOWN TITAN study group
Jul 11, 2008·AIDS·Roberto OrtizSabrina Spinosa-Guzman
Oct 2, 2008·HIV Medicine·B G GazzardUNKNOWN BHIVA Treatment Guidelines Writing Group
May 29, 2009·AIDS·Sandra De MeyerMarie-Pierre de Béthune
Dec 17, 2009·AIDS·Jose R ArribasChristiane Moecklinghoff
Jul 20, 2010·Lancet·Julio S G MontanerPerry Kendall
Feb 25, 2011·AIDS·Pedro CahnFrank Tomaka
Aug 4, 2011·PloS One·Sandra MathisHeiner C Bucher
Jan 19, 2012·International Journal of Epidemiology·Per Kragh AndersenHein Putter
Jun 15, 2012·AIDS·Marguerite GuiguetUNKNOWN FHDH-ANRS CO4
Aug 9, 2013·HIV Clinical Trials·G GuaraldiM Garau
Jan 15, 2014·The Journal of Antimicrobial Chemotherapy·Adrian CurranUNKNOWN PIMOCS Study Group
Feb 20, 2014·International Journal of Epidemiology·Murielle Mary-KrauseDominique Costagliola
Apr 5, 2014·Lancet·Bonaventura ClotetUNKNOWN ING114915 Study Team
May 17, 2014·The Journal of Antimicrobial Chemotherapy·D PodzamczerUNKNOWN KIDAR Study Group
Jul 20, 2014·JAMA : the Journal of the American Medical Association·Huldrych F GünthardPaul A Volberding
Sep 16, 2015·AIDS·Andrea AntinoriChristiane Moecklinghoff
Oct 2, 2015·The Lancet. HIV·Nicholas I PatonUNKNOWN Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) Trial Team
Oct 27, 2016·AIDS·Wolfgang StöhrUNKNOWN Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) Trial Team
Feb 17, 2017·PloS One·Amanda HäggblomVeronica Svedhem
Apr 13, 2017·BMC Infectious Diseases·Tony AntoniouUNKNOWN Canadian Observational Cohort (CANOC) collaboration
Oct 12, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Federico PulidoUNKNOWN DUAL-GESIDA-8014-RIS-EST45 Study Group
Mar 29, 2018·Scientific Reports·A AntinoriR Termini
Citations
Aug 25, 2020·Current Pharmacology Reports·Linzi FanChunjuan Yang
Dec 2, 2020·The Journal of Antimicrobial Chemotherapy·Valérie PotardUNKNOWN French Hospital Database on HIV (FHDH-ANRS CO4)
Oct 31, 2019·Global Health & Medicine·Manabu AokiHiroaki Mitsuya
Jan 8, 2021·Open Forum Infectious Diseases·Hélène ChaussadeFabrice Bonnet
May 29, 2021·Expert Opinion on Drug Safety·Camilla Ingrid HatlebergCaroline Sabin